Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based

recurrent disease
peritoneal cancer
fallopian tube
olaparib
parp inhibitor
  • 392 views
  • 10 Feb, 2021
  • 42 locations
Carboplatin and Paclitaxel With or Without Cediranib in Treating Women With Relapsed Ovarian Epithelial Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer

dividing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether combination

peritoneal cancer
fallopian tube
combination chemotherapy
paclitaxel
ovarian epithelial cancer
  • 41 views
  • 07 Nov, 2020
  • 6 locations
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with

peritoneal cancer
fallopian tube
tumor cells
pegylated liposomal doxorubicin hydrochloride
liver metastasis
  • 1729 views
  • 26 Feb, 2021
  • 212 locations
Does Cediranib With Paclitaxel or Cediranib and Olaparib Treat Advanced Endometrial Cancer Better Than Paclitaxel?

cediranib. Cediranib is a tablet medication and works by blocking new blood vessel formation. Cediranib has been tested in women with endometrial cancer before but not alongside chemotherapy treatment

recurrent endometrial cancer
cytotoxic chemotherapy
recurrent disease
metastasis
liver metastasis
  • 30 views
  • 23 Jan, 2021
  • 11 locations
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be

pancreatic adenocarcinoma
tumor cells
antihypertensive
ejection fraction
trastuzumab
  • 0 views
  • 27 Jan, 2021
  • 11 locations
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer

chemotherapy for advanced/recurrent disease. Patients will be randomised to either placebo Cediranib and Olaparib or active Cediranib and Olaparib and will remain on treatment until progression of disease

recurrent cervical cancer
recurrent disease
aptt
adenocarcinoma
anticoagulants
  • 0 views
  • 24 Jan, 2021
  • 1 location
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced

liver metastasis
tumor cells
endocrine therapy
antihypertensive
olaparib
  • 0 views
  • 26 Jan, 2021
Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer

survival (DFS) and overall survival (OS). Recent studies with addition of sorafenib and cediranib revealed promising effect on tumor response with acceptable toxicity. Regorafenib is a multi tyrosine

regorafenib
renal function
capecitabine
pelvic mri
endoscopy
  • 13 views
  • 30 Jan, 2021
  • 10 locations
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian Triple Negative Breast Lung Prostate and Colorectal Cancers

cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two components. In the phase 1 component of the study, researchers want to investigate how well

breast cancer
lung carcinoma
BRCA2
monoclonal antibodies
peritoneal cancer
  • 31 views
  • 27 Jan, 2021
  • 1 location
Basket Combination Study of Inhibitors of DNA Damage Response Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Leiomyosarcoma (LMS). Subjects will be stratified based on their primary malignancy and enrolled into one of the following cohorts: Cohort A: olaparib and durvalumab. Cohort B: cediranib

monoclonal antibodies
olaparib
anthracyclines
cancer chemotherapy
antiangiogenic agents
  • 4 views
  • 24 Jan, 2021
  • 1 location